Supplementary Materials

Supplementary Material for:

Local iontophoretic administration of cytotoxic therapies to solid tumors

James D. Byrne,* Mohammad R. N. Jajja,* Adrian T. O'Neill, Lissett R. Bickford, Amanda W. Keeler, Nabeel Hyder, Kyle Wagner, Allison Deal, Ryan E. Little, Richard A. Moffitt, Colleen Stack, Meredith Nelson, Christopher R. Brooks, William Lee, J. Chris Luft, Mary E. Napier, David Darr, Carey K. Anders, Richard Stack, Joel E. Tepper, Andrew Z. Wang, William C. Zamboni, Jen Jen Yeh,* Joseph M. DeSimone*

*Corresponding author. E-mail: jen_jen_yeh{at}med.unc.edu (J.J.Y.); desimone{at}unc.edu (J.M.D.)

Published 4 February 2015, Sci. Transl. Med. 7, 273ra14 (2015)
DOI: 10.1126/scitranslmed.3009951

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Gemcitabine transport into PDX tumors after a single device treatment.
  • Fig. S2. Drug transport through freshly excised murine skin.
  • Fig. S3. Role of gemcitabine concentration in drug transport in vitro.
  • Fig. S4. PK of cisplatin delivered transdermally by iontophoretic devices.
  • Fig. S5. Body weight changes in response to chemotherapy.
  • Fig. S6. Change in laboratory values after the device gemcitabine treatment schedule.
  • Fig. S7. Short-term renal toxicity after a single cisplatin treatment in mice.

[Download PDF]